Zoryve is Now Approved for Children with Plaque Psoriasis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      UNITED States. Food & Drug Administration
    • Abstract:
      The article focuses on the FDA's approval of Zoryve (roflumilast) cream 0.3 present for the topical treatment of plaque psoriasis in children aged 6 to 11, expanding its previous indication for those 12 and older. It mentions Zoryve offers a steroid-free, once-daily treatment for plaque psoriasis in children, and the dosage and pricing are the same for both pediatrics and adults.